BENEFIT Act of 2023

Bill: 118-hr-1092
Sponsor: full_name: Rep. Matsui, Doris O. [D-CA-7]
Introduced: 2023-02-17
Policy area: Health
Latest action: action_date: 2023-02-24
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2023-02-17
action_desc: Introduced in House
text: <p><b>Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023 or the BENEFIT Act of </b><b>2023</b></p> <p>This bill requires the Food and Drug Administration (FDA) to consider relevant patient experience data in the risk-benefit assessment framework used in the process for approving new drugs.</p> <p>After a new drug application has been approved, the FDA's public statement about how it used patient experience data shall include a description of how such data was considered in the risk-benefit assessment framework. </p>

tv_txt: I 118th CONGRESS 1st Session H. R. 1092 IN THE HOUSE OF REPRESENTATIVES February 17, 2023 Ms. Matsui (for herself and Mr. Wenstrup ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.

1. Short title This Act may be cited as the Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023 or the BENEFIT Act of 2023 . 2. Strengthening the use of patient-experience data within risk-benefit framework Section 569C of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–8c ) is amended— (1) in subsection (a)(1)— (A) in subparagraph (A), by striking ; and and inserting a semicolon; (B) in subparagraph (B), by striking the period and inserting ; and ; and (C) by adding at the end the following: (C) as part of the risk-benefit assessment framework in the new drug approval process described in section 505(d), considering patient experience data submitted by the medical product sponsor or another party. ; and (2) in subsection (b)(1), by inserting , including a description of how such data and information were considered in the risk-benefit assessment described in section 505(d) before the period at the end.